Jennifer L. Bryant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer L. Bryant has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Stewart Poklepovic
Virginia Commonwealth University Health System, Richmond, VA
23 shared publications - Craig L. Slingluff
Department of Surgery/Division of Surgical Oncology and the Human Immune Therapy Center, Cancer Center, University of Virginia, Charlottesville, USA
23 shared publications - David Brighton
University of Virginia 1 Charlottesville, VA
23 shared publications - Elizabeth Gaughan
University of Virginia 3 Charlottesville
23 shared publications - Emily K. Ninmer
University of Virginia 2 Charlottesville, Virginia
23 shared publications - Gina R. Petroni
University of Virginia 1 Charlottesville, VA
23 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Participant baseline characteristics by treatment arm.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Participant baseline characteristics by treatment arm.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Trial design and protocol amendment for safety. A and B, Trial schema of study interventions (A) before and (B) after protocol amendment for exceeding the DLT threshold. Vaccines included poly-ICLC in the adjuvant at all time points except for week 25, represented by the dashed arrow. Blood draws were obtained prior to vaccination and/or varlilumab therapy. C, CONSORT flow diagram. ID, intradermal; IV, intravenous; SQ, subcutaneous.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Trial design and protocol amendment for safety. A and B, Trial schema of study interventions (A) before and (B) after protocol amendment for exceeding the DLT threshold. Vaccines included poly-ICLC in the adjuvant at all time points except for week 25, represented by the dashed arrow. Blood draws were obtained prior to vaccination and/or varlilumab therapy. C, CONSORT flow diagram. ID, intradermal; IV, intravenous; SQ, subcutaneous.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S7 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Immune response rates by protocol version
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S7 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Immune response rates by protocol version
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S9 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Changes in absolute number of circulating CD4+ T cells over time
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S9 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Changes in absolute number of circulating CD4+ T cells over time
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 3 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Impact of treatment on circulating CD4+ T cells over time. Participants (arm A n = 10; arm B n = 12) were evaluated for changes in circulating T cells from baseline by repeated measures modeling of log10-transformed data: (A) absolute number of Tregs, (B) absolute number of CD4+ T cells, and (C) Tregs as a percentage of CD4+ T cells. Each participant is represented by a dashed line, and the solid lines represent the model estimated change from baseline with 95% CI for each arm.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Impact of treatment on circulating CD4+ T cells over time. Participants (arm A n = 10; arm B n = 12) were evaluated for changes in circulating T cells from baseline by repeated measures modeling of log10-transformed data: (A) absolute number of Tregs, (B) absolute number of CD4+ T cells, and (C) Tregs as a percentage of CD4+ T cells. Each participant is represented by a dashed line, and the solid lines represent the model estimated change from baseline with 95% CI for each arm.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Flow cytometry gating of circulating Tregs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Flow cytometry gating of circulating Tregs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary File 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Supplementary File 1 - Protocol
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File 1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Supplementary File 1 - Protocol
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Representativeness of study participants
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Representativeness of study participants
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure 4 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Clinical outcomes by arm. Kaplan–Meier survival curves with 95% CI by arm for (A) DFS and (B) OS.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Randomized Phase I/II Clinical Trial of a Melanoma Helper Peptide Vaccine with or without Systemic Agonistic Anti-CD27 Antibody (Varlilumab)
Clinical outcomes by arm. Kaplan–Meier survival curves with 95% CI by arm for (A) DFS and (B) OS.